

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
00030/0095	Novartis Consumer Health UK Ltd	Eurax Lotion	Crotamiton 10-000 w/w	dermatitis, intertrigo, prurigo nodularis, seborrhoeic dermatitis and insect bite reactions. (See PL/00030/0093) Prescription Only Medicine 1. For the relief of itching and skin irritation caused by, for example sunburn, dry eczema, itchy dermatitis, allergic rashes, hives, nettle rash, chickenpox, insect bites and stings, heat rashes and personal itching. 2. The treatment of scabies. General Sales List	1st September 1997
00030/0096	Novartis Consumer Health UK Ltd	Do-Do Chestez Bronchial Syrup Do-Do Expectorant Linctus	Guaiphenesin BP 100 mg	Productive and non-productive cough associated with irritation or infection of the upper respiratory tract. General Sales List	14th September 1997
00030/0101	Novartis Consumer Health UK Ltd	Mu-Cron Tablets	Paracetamol (DC 96%) 520.8 mg Phenylpropanolamine Hydrochloride BP 25.0 mg	Relief of sinus pain, nasal congestion and catarrh. Symptomatic relief of nasal congestion caused by hay fever. Symptomatic relief of influenza, feverishness and feverish colds. Pharmacy Medicine	1st September 1997
00030/0102	Novartis Consumer Health UK Limited	Junior Mu-Cron Syrup	Phenylpropanolamine Hydrochloride BP 6.25 mg Vinegar or Ipecacuanha BPC 1949 BPC 104.0 mg	To relieve the symptoms of nasal congestion associated with the common cold, catarrh, chesty coughs and hay fever. Pharmacy Medicine	1st September 1997
00030/0121	Novartis Consumer Health UK Limited	Savlon Antiseptic Wound Wash/Savlon Junior	Chlorhexidine Gluconate Solution BP 2.25 v/v	For the cleansing and disinfection of minor wounds, cuts, grazes and minor abrasions including insect bites and stings. General Sales List	14th September 1997
00053/0053	Schering Health Care Limited	Cyclo-Progynova 2 mg	White Coated Tablets: Oestradiol Valerate USP 2.0 mg Pale Brown Coated Tablets: Norgestrel USP 0.5 mg Oestradiol Valerate USP 2.0 mg	Hormone replacement therapy for the treatment of the climacteric syndrome. Prevention of postmenopausal osteoporosis in women considered at risk of developing fractures. Prescription Only Medicine	1st September 1997
00053/0108	Schering Health Care Limited	Cyclo-Progynova 1 mg	Each Beige Tablet contains: Oestradiol Valerate USP 1.0 mg Each Light Brown Tablet contains: Oestradiol Valerate USP 1.0 mg Levonorgestrel EP 0.25 mg	Hormone replacement therapy for the treatment of the climacteric syndrome. Prescription Only Medicine	1st September 1997
00079/0338	Beecham Group PLC	OXY On-the-Spot	Benzoyl Peroxide 2.500 ww	For the treatment of spots and pimples on the face. General Sales List	22nd September 1997
00086/0211	Hoechst UK Limited	Oestrogel Pump-Pack	Oestradiol Hemihydrate -062 ww	As oestrogen replacement therapy for the relief of symptoms due to natural or surgically induced menopause such as vasomotor symptoms (hot flushes and sweating), atrophic vaginitis and atrophic urethritis. Prescription Only Medicine	1st September 1997
00101/0485	Novartis Pharmaceuticals UK Ltd.	Estracombi TTS	Estraderm TTS 50 Oestradiol USP 40 mg Estragel TTS Norethisterone Acetate, Micronised BSP 300 mg Oestradiol USP 100 mg	Hormone replacement therapy for patients with disorders due to natural or surgically induced menopause, eg vasomotor symptoms (hot flushes and nocturnal sweating), urogenital conditions such as atrophic vaginitis/vulvitis, and/or atrophic urethritis and trigonitis. Prevention of postmenopausal osteoporosis in women considered at risk of developing fractures. Epidemiological studies suggest a number of risk factors may contribute to postmenopausal osteoporosis, including: Early menopause (either natural or surgically induced) Family history of osteoporosis Recent prolonged corticosteroid therapy A small, thin frame Excessive cigarette consumption If several risk factors are present, consideration should be given to hormone replacement therapy. Bone mineral density measurements may help to confirm the presence of low bone mass. For maximum prophylactic benefit treatment should commence as soon as possible after the menopause. Prescription Only Medicine	12th September 1997
00101/0486	Novartis Pharmaceuticals UK Limited	Estraderm MX 25	Oestradiol Hemihydrate -770 mg	Oestrogen replacement therapy for patients with disorders due to natural or surgically induced menopause, eg vasomotor symptoms (hot flushes and nocturnal sweating), urogenital conditions such as atrophic vaginitis/vulvitis, and/or atrophic urethritis and trigonitis. Prevention of postmenopausal osteoporosis in women considered	12th September 1997